Characterization of daunorubicin-induced apoptosis in retinal pigment epithelial cells: Modulation by CD95L

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 7, 2003, Pages 2851-2857

  Hueber, Arno ^a   Weller, Michael ^b   Welsandt, Gerhard ^a   Kociok, Norbert ^a   Kirchhof, Bernd ^a   Esser, Peter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CRYSTAL VIOLET; CYTOKINE; DAUNORUBICIN; DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; HISTONE; INTERLEUKIN 1BETA CONVERTING ENZYME; LEUCINE; PROTEIN; RNA; URIDINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURFACE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; NICK END LABELING; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; SIDE EFFECT; VITREORETINOPATHY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; APOPTOSIS; CASPASE 1; CASPASE 3; CASPASES; CELLS, CULTURED; DAUNORUBICIN; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IN SITU NICK-END LABELING; MEMBRANE GLYCOPROTEINS; PIGMENT EPITHELIUM OF EYE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0038577090     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-1178     Document Type: Article

References (28)

1. Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathy: is it anything more than wound healing at the wrong place? Int Ophthalmol. 1990;14:105-117.
2. Wiedemann P, Lemmen K, Schmiedl R, Heimann K. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol. 1987;104:10-14.
3. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126:550-559.
4. Steinhorst UH, Hatchell DL, Chen EP, Machemer R. Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression. Graefes Arch Clin Exp Ophthalmol. 1993;231:591-594.
5. Esser P, Tervooren D, Heimann K, et al. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39:164-170.
6. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood. 2001;98:913-924.
7. Sartorius U, Schmitz I, Krammer PH. Molecular mechanisms of death-receptor-mediated apoptosis. ChemBioChem. 2001;2:20-29.
8. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
9. Sotozono C, Sano Y, Suzuki T, et al. Soluble Fas ligand expression in the ocular fluids of uveitis patients. Curr Eye Res. 2000;20:54-57.
10. Mochizuki M, Sugita S, Ishikawa N, Watanabe T. Immunoregulation by aqueous humor. Cornea. 2000;19:S24-S25.
11. Machemer R, Laqua H. Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975;80:1-23.
12. Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol. 1995;25:2253-2258.
13. Hueber A, Esser P, Heimann K, Kociok N, Winter S, Weller M. The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells. Exp Eye Res. 1998;67:525-530
14. Hueber A, Wiedemann P, Esser P, Heimann K. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int Ophthalmol. 1997;20:345-350.
15. Kippenberger S, Loitsch S, Solano F, Bernd A, Kaufmann R. Quantification of tyrosinase, TRP-1, and Trp-2 transcripts in human melanocytes by reverse transcriptase-competitive multiplex PCR-regulation by steroid hormones. J Invest Dermatol. 1998;110:364-367.
16. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells: induction and modulation of sensitivity by cytokines. J Clin Invest. 1994;94:954-964.
17. Wagenknecht B, Schulz JB, Gulbins E, Weller M. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death Diff. 1998;5:894-900.
18. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother. 1997;44:55-63.
19. Webb JL. Effects of more than one inhibitor. In: Enzyme and Metabolic Inhibitors: General Principles of Inhibition. New York: Academic Press; 1963:487-512.
20. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood. 2001;98:2603-2614.
21. Esser P, Heimann K, Abts H, Fontana A, Weller M. CD95 (Fas/APO-1) antibody-mediated apoptosis of human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1995;213:1026-1034.
22. Weller M, Heimann K, Bartz-Schmidt KU, Fontana A, Esser P. CD 95 expression in traumatic proliferative vitreoretinopathy: a target for the induction of apoptosis. Ger J Ophthalmol. 1996;5:332-337.
23. Yamaoka M, Yamaguchi S, Suzuki T, et al. Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol. 2000;32:881-889.
24. Labroille G, Dumain P, Lacombe F, Belloc F. Flow cytometric evaluation of fas expression in relation to response and resistance to anthracyclines in leukemic cells. Cytometry, 2000;39:195-202.
25. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57:3823-3829.
26. Nakamura S, Takeshima M, Nakamura Y, Ohtake S, Matsuda T. Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-fas monoclonal antibody. Anticancer Res. 1997;17:173-179.
27. Glaser T, Wagenknecht B, Weller M. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene. 2001;20:4757-4767.
28. Glaser T, Wagenknecht B, Groscurth P, Krammer PH, Weller M. Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene. 1999;18:5044-5053.